<DOC>
	<DOC>NCT01025479</DOC>
	<brief_summary>Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti androgen</brief_summary>
	<brief_title>Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Androgen Antagonists</mesh_term>
	<criteria>pathologic confirmation of prostate cancer patients who are taking LHRH antagonist or anti androgen or both of them within 6 months since starting. patients who are hard to be analysed by limitation of chart record according to investigators'discretion patients who already have been registered in this study</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>LHRH agonist and/or anti-androgen agent</keyword>
	<keyword>Korean prostate cancer</keyword>
</DOC>